Fundamental Analysis of SAB BIOTHERAPEUTICS INC(NASDAQ:SABS) stock

Fundamental Rating

Overall SABS gets a fundamental rating of 1 out of 10. We evaluated SABS against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of SABS have multiple concerns. SABS has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

SABS had negative earnings in the past year.

In the past year SABS has reported a negative cash flow from operations.

1.2 Ratios

SABS's Return On Assets of -84.70% is on the low side compared to the rest of the industry. SABS is outperformed by 71.33% of its industry peers.

SABS's Return On Equity of -123.48% is in line compared to the rest of the industry. SABS outperforms 40.18% of its industry peers.

		Industry Rank	Sector Rank
ROA	-84.7%
ROE	-123.48%
ROIC	N/A

ROA(3y)-36.07%

ROA(5y)N/A

ROE(3y)-59.48%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SABS has been increased compared to 1 year ago.

Compared to 1 year ago, SABS has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -4.22, we must say that SABS is in the distress zone and has some risk of bankruptcy.

SABS has a Altman-Z score of -4.22. This is comparable to the rest of the industry: SABS outperforms 41.24% of its industry peers.

SABS has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of SABS (0.09) is worse than 64.78% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	-4.22

ROIC/WACCN/A

WACC11.52%

2.3 Liquidity

A Current Ratio of 3.69 indicates that SABS has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 3.69, SABS is in line with its industry, outperforming 43.72% of the companies in the same industry.

A Quick Ratio of 3.69 indicates that SABS has no problem at all paying its short term obligations.

SABS has a Quick ratio (3.69) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.69
Quick Ratio	3.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for SABS have decreased strongly by -43.66% in the last year.

SABS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.05%.

The Revenue for SABS have been decreasing by -65.65% on average. This is quite bad

EPS 1Y (TTM)-43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-12%

Revenue 1Y (TTM)-63.05%

Revenue growth 3Y-65.65%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 17.69% on average over the next years. This is quite good.

SABS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.35% yearly.

EPS Next Y49.25%

EPS Next 2Y27.11%

EPS Next 3Y17.69%

EPS Next 5YN/A

Revenue Next Year4.91%

Revenue Next 2Y-12.85%

Revenue Next 3Y-1.72%

Revenue Next 5Y-5.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SABS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SABS's earnings are expected to grow with 17.69% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y27.11%

EPS Next 3Y17.69%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SABS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (12/18/2024, 5:29:34 PM)

After market: 3.41 +0.07 (+2.1%)

3.34

-0.69 (-17.12%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap30.83M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-84.7%
ROE	-123.48%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.69
Quick Ratio	3.69
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-43.66%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y49.25%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-63.05%

Revenue growth 3Y-65.65%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SAB BIOTHERAPEUTICS INC (SABS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens